ArticleEFSA journal. European Food Safety Authority2023
Avian influenza overview June-September 2023.
Article in EFSA journal. European Food Safety Authority, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Understanding zoonotic pathogens and risk factors from wildlife in Southeast Asia: a systematic literature review.The veterinary quarterly · 2025Pooled it
- Counting cases, conserving species: addressing highly pathogenic avian influenza in wildlife.Biological reviews of the Cambridge Philosophical Society · 2026Review
- The role of wild birds in the global highly pathogenic avian influenza H5 panzootic, 2020-2023.npj biodiversity · 2026Review
- An HLAII-targeted DNA vaccine against influenza H7N9 protected mice and ferrets from a virus challenge.NPJ vaccines · 2025Article
- Article
- Genetic Diversity of Highly Pathogenic Avian Influenza Viruses Isolated in Hokkaido, Japan, During Winter 2024-2025.Pathogens (Basel, Switzerland) · 2025Article
- Update on Ophthalmic Implications of Highly Pathogenic Avian Influenza A (H5N1) Virus.Pathogens (Basel, Switzerland) · 2025Review
- Clade 2.3.4.4b highly pathogenic avian influenza H5N1 viruses: knowns, unknowns, and challenges.Journal of virology · 2025Review
- Genetic diversity of A(H5N1) avian influenza viruses isolated from birds and seals in Russia in 2023.Scientific reports · 2025Article
- Genetic diversity of highly pathogenic avian influenza H5N6 and H5N8 viruses in poultry markets in Guangdong, China, 2020-2022.Journal of virology · 2025Article
- Asymptomatic infection and antibody prevalence to co-occurring avian influenza viruses vary substantially between sympatric seabird species following H5N1 outbreaks.Scientific reports · 2025Article
- Highly Pathogenic Clade 2.3.4.4b H5N1 Influenza Virus in Seabirds in France, 2022-2023.Transboundary and emerging diseases · 2025Article
- Assessing the Use of Different Surveillance Components to Detect Highly Pathogenic Avian Influenza Outbreaks in Poultry in the Netherlands in Low- and High-Risk Years.Transboundary and emerging diseases · 2025Article
- Avian influenza annual report 2023.EFSA journal. European Food Safety Authority · 2025Article
- Article
- Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in Cats, South Korea, 2023.Emerging infectious diseases · 2024Article
- Surveillance for Avian Influenza in Wild Birds in the Lombardy Region (Italy) in the Period 2022-2024.Viruses · 2024Article
- Highly pathogenic avian influenza management policy in domestic poultry: from reacting to preventing.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Avian influenza overview June-September 2024.EFSA journal. European Food Safety Authority · 2024Article
- The Alarming Situation of Highly Pathogenic Avian Influenza Viruses in 2019-2023.Global medical genetics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Between 24 June and 1 September 2023, highly pathogenic avian influenza (HPAI) A(H5) outbreaks were reported in domestic (25) and wild (482) birds across 21 countries in Europe. Most of these outbreaks appeared to be clustered along coastlines with only few HPAI virus detections inland. In poultry, all HPAI outbreaks were primary and sporadic with most of them occurring in the United Kingdom. In wild birds, colony-breeding seabirds continued to be most heavily affected, but an increasing number of HPAI virus detections in waterfowl is expected in the coming weeks. The current epidemic in wild birds has already surpassed the one of the previous epidemiological year in terms of total number of HPAI virus detections. As regards mammals, A(H5N1) virus was identified in 26 fur animal farms in Finland. Affected species included American mink, red and Arctic fox, and common raccoon dog. The most likely source of introduction was contact with gulls. Wild mammals continued to be affected worldwide, mostly red foxes and different seal species. Since the last report and as of 28 September 2023, two A(H5N1) clade 2.3.4.4b virus detections in humans have been reported by the United Kingdom, and three human infections with A(H5N6) and two with A(H9N2) were reported from China, respectively. No human infection related to the avian influenza detections in animals on fur farms in Finland or in cats in Poland have been reported, and human infections with avian influenza remain a rare event. The risk of infection with currently circulating avian H5 influenza viruses of clade 2.3.4.4b in Europe remains low for the general population in the EU/EEA. The risk of infection remains low to moderate for occupationally or otherwise exposed people to infected birds or mammals (wild or domesticated); this assessment covers different situations that depend on the level of exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.